GSK: FDA approves new meningitis vaccine
(CercleFinance.com) - GSK announced this weekend that the US FDA had approved Penmenvy, a new vaccine to prevent meningitis caused by a wide range of meningococcal strains.
The British pharmaceutical company explains that Penmenvy has been approved to protect children, adolescents and young adults aged between 10 and 25 years against serogroups A, B, C, W and Y belonging to the Neisseriaceae family.
The vaccine combines two existing products: Bexsero, indicated to prevent meningococcal meningitis caused by serogroup B, the most common in the young population, and Menveo, which protects against infections caused by serogroups A, C, Y and W-135.
Meningococcal disease can rapidly lead to death or disability in previously healthy adolescents, even after early and appropriate treatment.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
The British pharmaceutical company explains that Penmenvy has been approved to protect children, adolescents and young adults aged between 10 and 25 years against serogroups A, B, C, W and Y belonging to the Neisseriaceae family.
The vaccine combines two existing products: Bexsero, indicated to prevent meningococcal meningitis caused by serogroup B, the most common in the young population, and Menveo, which protects against infections caused by serogroups A, C, Y and W-135.
Meningococcal disease can rapidly lead to death or disability in previously healthy adolescents, even after early and appropriate treatment.
Copyright (c) 2025 CercleFinance.com. All rights reserved.